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Abstract 
 Effect of a synthetic Aluminium – Magnesium Silicate (AMS) on antiplasmodial  activity of 
chloroquine was tested.Plasmodium berghei infected mice  were treated with  7 mg/ kg, 5 mg / 
kg and 3 mg / kg chloroquine, respectively.Subgroups in each experiment were treated with 
chloroquine alone and with chloroquine  in  AMS.Parasitaemia (%)  of the group treated with  7 
mg / kg was higher than that of the control.At 5 mg / kg, chloroquine treatment reduced 
parasitaemia from 3.60  to 2.46  (P =   ).Incorporating chloroquine in  AMS 
improved its ability to reduce P.berghei  parasitaemia at 5 mg /kg and at 3 mg / kg, from  2.46  
0.21 to 1.57 0.25 (P = ) and from  3.82  0.06 to 2.12 0.08 (P = ). It also increased mortality 
of mice treated at 7 mg / kg from 20  to 80 % (P =   ). 
 
Key words: Antiplasmodial resistance, chloroquine toxicity, Aluminium – Magnesium Silicate, 
chloroquine phosphate. 
 
Background. 
 
Protozoan parasites of the genus plasmodium are causative agents of malaria1, 2. Malaria is a 
zoonotic disease , affecting man, zoo primates, avian species and rodents3,4. It has also been 
reported that when species of plasmodium which infect animals were passaged in human 
volunteers they produced malaria in man5. 
 
In humans, malaria is cause of between one to three million deaths in sub saharan Africa every 
year 6.Malaria is not only an effect of poverty it is also a cause of poverty7.To combat malaria, 
most countries in Africa spend upto 40 % of their public health budget on the disease annually8. 
Chloroquine is one of the drugs of choice for prevention and treatment of malaria in the 
developing countries,because, it is cheap and effective9.However, in recent times cases of 
resistance to chloroquine by malaria parasites have been reported10. Need therefore exists to 
search for drugs to combine with chloroquine to improve its efficacy and still retain its low cost. 
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Aluminium – Magnesium Silicate (AMS) is cheap. It is also safe to combine with drugs for 
treatment of man and animals11. When in solution its molecules form three dimentional 
colloidal structures round molecules of any drug it is combined with. By that mechanism, AMS 
stabilizes other drugs . To stabilize means to protect the drugs from destruction . AMS may thus 
protect chloroquine from being rapidly degraded by metabolic processes. This will retain high 
concentration of chloroquine in blood of treated animals for a long time.  When high 
concentrations of drugs are retained in blood for a long time, actions of such drugs are 
improved12.  By incorporating piperazine and sulphadimidin in the synthetic AMS their activity 
against Helignosomoides barkeri and Eimeria spp respectively, were improved13,14. A formulation 
of 20 %  chloroquine phosphate in a synthetic Aluminium – Magnesium Silicate was therefore 
made  to test if  the AMS would improve its antiplasmodial activity. 
 
Summary of Methods 
Thirty five mice were infected by innoculating each mouse with 1 ml of blood which contained 2 
105  parasitized Red Blood Cells. Ten days post infection (PI), they were divided into three 
experimental groups of 10 mice each. A group of five of the P. berghei infected mice was left 
untreated to serve as control. Each experimental group was subdivided into two, each of five 
mice . The experiments were done with chloroquine phosphate at 7 mg / kg, 5 mg /kg and 3 mg 
/ kg respectively. The two groups in each experiment were treated with  chloroquine phosphate 
alone and with  a drug formulation of 20 % chloroquine phosphate in the synthetic AMS 
respectively.Chloroquine treatment was administered per os, daily for five days in each 
experiment.   
 
A day post treatment (PT), percentage parasitaemia,rectal temperature,total Red Blood Cell 
(RBC) count and Heamoglobin concentration (Hb) were determined for each mouse in the  six 
treated  groups and control .This was repeated one week, two weeks and three weeks  PT. Mean 
values for each group were recorded as the group`s weekly values. 
 
Findings 
 
 Four  mice (80 %)  and one mouse (20 % ) of the groups  treated with 7 mg / kg chloroquine in 
AMS and 7 mg / kg chloroquine alone respectively, died between 7 to 14 days PT.Incorporating 
chloroquine phosphate in the AMS significantly improved its ability to reduce  P. berghei mean 
percentage parasitaemia at 5 mg / kg and 3 mg / kg dose levels, from  2.46 0.21 to 1.57  0.25 
(P =  ) and from 3.82  0.06 to 2.12 0.08 ( P = ) . Percentage mean  parasitaemia, 4.15  0.26 
of the group treated with 7 mg / kg chloroquine phosphate alone, was higher than 3.60  0.22 
of the control ( P = ).  
 
Mean Hb of 12.95 0.25 ,12.25  0.27  and 12.68  0.18 of the groups treated with 7 mg / kg 
chloroquine alone, 5 mg / kg chloroquine alone and 5 mg / kg chloroquine in AMS respectively, 
were higher (P = ) than  10.18  3.00  got in the group treated with 3 mg / kg chloroquine alone. 
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Also, RBC counts of  95.19 2.81 , 92.91  4.01 and 95.23  5.32  of the groups treated with 7 
mg / kg chloroquine phosphate alone,  5 mg / kg chloroquine phosphate in the AMS and 3 mg / 
kg chloroquine phosphate in AMS respectively, were higher (P = ) than 88.99 5.72 of the group 
treated with  5 mg / kg chloroquine alone . They were also more significantly ( P = ) higher than 
63.39  8.02 of the group treated with 3 mg / kg chloroquine alone. 
 
Mean rectal temperature,35.56  0.82   and 35.73   0.38 of the groups treated with 5 mg / 
kg chloroquine alone and 5 mg / kg chloroquine in AMS respectively, were significantly (P = ) 
lower than 36.84 0.32  , 36.84 0.23  and 36.16 0.35 got in the groups treated with 7 
mg / kg chloroquine alone, 3 mg / kg chloroquine in AMS and in the control respectively.  Effect 
of the synthetic AMS on ability of chloroquine phosphate to reduce P. berghei parasitaemia is as 
in table 1. 
 
Discussion 
                 Treatment with chloroquine in AMS reduced P.berghei parasitaemia,  significantly, more than 
treatment with chloroquine alone. Vanderbilt11 reported that AMS is a stabilizing agent.The three 
dimentional colloidal structures it forms round molecules of active drugs protect them from degradation 
by metabolic processes. The synthetic AMS may have protected chloroquine from being rapidly 
degraded  in blood of the treated mice. Retention of high concentrations of chloroquine in  blood of the 
mice for longer time may have led to  the significant reduction in parasitaemia. 
 Dose of chloroquine usually employed in treatment of malaria in humans, is 7 mg / kg but in this 
experiment,  mice treated with that dose had apparently higher parasitaemia than the untreated 
group.This may have been due to chloroquine toxicity. Chloroquine inhibits uptake of iron and destroys 
plasmodium infected Rbcs15,16 . Chloroquine toxicity also, results in immunosupression17 and it has no 
effect on parasites in tissues. Plasmodial parasites in tissues return to blood  once concentration of the 
drug in blood falls16. In immunosupressed animals, parasites that return to blood could have  rapid 
multiplication. So, the high parasitaemia in the  group treated with 7 mg /kg chloroquine alone, may be 
due to  chloroquine toxicity. There was no mortality in the group of untreated mice . So, the deaths 
recorded in the two groups treated at chloroquine dose of 7 mg / kg may  also be due to  chloroquine 
toxicity. The 20 % mortality of the group treated with chloroquine alone is significantly lower than 80 % 
mortality of the chloroquine in AMS group. This, also,  suggests that the AMS potentiated action of  
chloroquine. 
 
 Wellem10 reported that it is necessary to include supportive treatments, such as iron and vitamines to 
malarial therapy for effective treatment. None  inclusion of these surpotive treatments in the 
experiments may be responsible for the high parasitaemia  and mortalities recorded when chloroquine 
was used at dose of 7mg / kg. 
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RBC counts and Hb values of the groups of mice treated  with 7 mg / kg chloroquine alone, 5 mg / kg 
chloroquine in AMS and  3 mg / kg chloroquine in AMS  were high, indicating that the mice had no 
anaemia but the group treated with  5 mg / kg chloroquine alone and the control had slight anaemia. 
Anaemia was more pronounced in the group treated with 3 mg / kg chloroquine alone.  Both 
chloroquine toxicity and malaria cause anaemia15,18 . So, anaemia  of the groups treated with 5 mg / kg 
chloroquine alone and  3 mg / kg chloroquine alone, may be a result of ineffective treatment of the 
plasmodial infections. High mean rectal temperature got in the  group treated with  3 mg / kg 
chloriquine alone  may also be due to same reason. In the experiment with 5 mg / kg, the low 
parasitaemia achieved and the lower dose of chloroquine used may be responsible for absence of 
anaemia and fever in the two groups. 
The control group had only slight reduction in RBC count and in Hb. This finding agrees with report of  
Carter and Diggs19 that plasmodiun infection in rats and mice does not produce serious clinical disease.  
It has therefore been concluded that use of  chloroquine at dose of  5 mg / kg in  drug formulation of 
chloroquine and AMS may achieve better antiplasmodial action and  reduce chloroqune toxicity that 
occured even at the 7 mg / kg which is  presently being recomended. Supportive treatment with iron 
and vitamines may improve  treatment of malaria with chloroquine further. 
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    Table 1: Effect of the synthetic Aluminum-Magnesium Silicate on Plasmodium 
berghei parasitaemia of mice treated with chloroquine phosphate.  
 
Weeks Post 
Treatment  
PARASITAEMIA (%) 
 
 7mg/kg CQ 7mg/kg 
CQ-AMS 
5mg/kg CQ 5mg/kg 
CQ-AMS 
3mg/kg 
CQ 
3mg/kg 
CQ AMS 
Control 
Week 0 4.50 5.00 2.62 1.12 3.88 2.24 3.64 
Week 1 4.40 4.60 2.20 1.16 3.96 2.04 2.96 
Week 2 4.30 Dead 2.97 2.12 3.68 1.92 3.85 
Week 3 3.38 Dead 2.06 1.86 3.76 2.28 3.93 
Mean   
 
4.15 ±0.26c  2.46±0.21 
abc 
1.57±0.25a 3.82±0.06bc 2.12 
±0.08ab 
3.69±0.22 
bc 
 
Different superscripts abc in a row indicates significant differences between the means at the level 
of probability: P ≤ 0.05 
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